-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
About 1.
ALN-AGT is an RNAi therapy targeting mRNA that expresses angiotensinogen.
In this randomized, double-blind, placebo-controlled clinical trial, a total of 84 hypertensive patients received different doses of ALN-AGT.
Moreover, as the AGT level drops, the patient's blood pressure also drops at the same time.
Note: The original text has been deleted
Reference materials:
[1] Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension.
[2] Safety, Pharmacodynamics, and Blood Pressure Effects of ALN-AGT, an RNA Interference Therapeutic Targeting Angiotensinogen, in a Randomized Single Ascending Dose Study of Hypertensive Adults.